Dasatinib for the treatment of Philadelphia chromosome-positive leukemias

Fabio P.S. Santos, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Introduction: Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI), which was developed to treat patients with chronic myelogenous leukemia (CML), who had failed or were intolerant to therapy with imatinib. Areas covered: In this article, we review preclinical and clinical studies with dasatinib for the therapy of Philadelphia (Ph)-positive leukemias. Expert opinion: Dasatinib is very effective in the setting of CML resistance or intolerance to imatinib, particularly in patients in chronic phase (CP). Dasatinib is also effective against most BCR-ABL1 mutations that arise during therapy with imatinib. Further studies have confirmed activity of dasatinib as a single-agent, and combined with chemotherapy, for the treatment of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+-ALL). More recently, randomized trials have demonstrated that dasatinib is superior to imatinib in the initial therapy of patients with CML, and the drug was approved by the FDA for this indication in 2011.

Original languageEnglish (US)
Pages (from-to)2381-2395
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number16
DOIs
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
src-Family Kinases
Expert Testimony
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dasatinib
Drug Therapy
Mutation
Imatinib Mesylate
Pharmaceutical Preparations

Keywords

  • Acute lymphoblastic leukemia
  • BCR-ABL
  • chronic myelogenous leukemia
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. / Santos, Fabio P.S.; Cortes, Jorge.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 16, 01.11.2012, p. 2381-2395.

Research output: Contribution to journalReview article

@article{b2475df4c0ac4098aebd6cd514952597,
title = "Dasatinib for the treatment of Philadelphia chromosome-positive leukemias",
abstract = "Introduction: Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI), which was developed to treat patients with chronic myelogenous leukemia (CML), who had failed or were intolerant to therapy with imatinib. Areas covered: In this article, we review preclinical and clinical studies with dasatinib for the therapy of Philadelphia (Ph)-positive leukemias. Expert opinion: Dasatinib is very effective in the setting of CML resistance or intolerance to imatinib, particularly in patients in chronic phase (CP). Dasatinib is also effective against most BCR-ABL1 mutations that arise during therapy with imatinib. Further studies have confirmed activity of dasatinib as a single-agent, and combined with chemotherapy, for the treatment of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+-ALL). More recently, randomized trials have demonstrated that dasatinib is superior to imatinib in the initial therapy of patients with CML, and the drug was approved by the FDA for this indication in 2011.",
keywords = "Acute lymphoblastic leukemia, BCR-ABL, chronic myelogenous leukemia, Philadelphia chromosome",
author = "Santos, {Fabio P.S.} and Jorge Cortes",
year = "2012",
month = "11",
day = "1",
doi = "10.1517/14656566.2012.725722",
language = "English (US)",
volume = "13",
pages = "2381--2395",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "16",

}

TY - JOUR

T1 - Dasatinib for the treatment of Philadelphia chromosome-positive leukemias

AU - Santos, Fabio P.S.

AU - Cortes, Jorge

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Introduction: Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI), which was developed to treat patients with chronic myelogenous leukemia (CML), who had failed or were intolerant to therapy with imatinib. Areas covered: In this article, we review preclinical and clinical studies with dasatinib for the therapy of Philadelphia (Ph)-positive leukemias. Expert opinion: Dasatinib is very effective in the setting of CML resistance or intolerance to imatinib, particularly in patients in chronic phase (CP). Dasatinib is also effective against most BCR-ABL1 mutations that arise during therapy with imatinib. Further studies have confirmed activity of dasatinib as a single-agent, and combined with chemotherapy, for the treatment of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+-ALL). More recently, randomized trials have demonstrated that dasatinib is superior to imatinib in the initial therapy of patients with CML, and the drug was approved by the FDA for this indication in 2011.

AB - Introduction: Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI), which was developed to treat patients with chronic myelogenous leukemia (CML), who had failed or were intolerant to therapy with imatinib. Areas covered: In this article, we review preclinical and clinical studies with dasatinib for the therapy of Philadelphia (Ph)-positive leukemias. Expert opinion: Dasatinib is very effective in the setting of CML resistance or intolerance to imatinib, particularly in patients in chronic phase (CP). Dasatinib is also effective against most BCR-ABL1 mutations that arise during therapy with imatinib. Further studies have confirmed activity of dasatinib as a single-agent, and combined with chemotherapy, for the treatment of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+-ALL). More recently, randomized trials have demonstrated that dasatinib is superior to imatinib in the initial therapy of patients with CML, and the drug was approved by the FDA for this indication in 2011.

KW - Acute lymphoblastic leukemia

KW - BCR-ABL

KW - chronic myelogenous leukemia

KW - Philadelphia chromosome

UR - http://www.scopus.com/inward/record.url?scp=84867656794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867656794&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.725722

DO - 10.1517/14656566.2012.725722

M3 - Review article

C2 - 22992064

AN - SCOPUS:84867656794

VL - 13

SP - 2381

EP - 2395

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -